Saporin Conjugated Monoclonal Antibody to the Transcobalamin Receptor TCblR/CD320 Is Effective in Targeting and Destroying Cancer Cells
- 1 Department of Medicine, SUNY-Downstate Medical Center, Brooklyn, USA
- 2 Department of Medicine, SUNY-Downstate Medical Center, Brooklyn, USA
- 3 Department of Medicine, SUNY-Downstate Medical Center, Brooklyn, USA
Abstract
Cobalamin uptake into cells is mediated by the CD 320 receptor for transcobalamin-bound cobalamin. Optimum rec e p tor expression is associated with proliferating cells and therefore, in many cancers this receptor expression is up regu lated. Delivering drugs or toxins via this receptor provides increased targeting to cancer cells while minimizing toxicity to the normal tissues. Saporin conjugated monoclonal antibodies to the extracellular domain of TCblR were effectively internalized to deliver a toxic dose of Saporin to some cancer cell lines propagating in culture. Antibody concentration of 2.5 nM was effective in producing optimum inhibition of cell proliferation. The cytotoxic effect of mAb-Saporin appears to be dictated primarily by the level of receptor expression and therefore normal primary cells expressing low levels of CD 320 were spared while tumor cell lines with higher CD 320 expression were destroyed. Targeting the path way for cellular uptake of vitamin B 12 via the CD 320 receptor with toxin-antibody conjugates appears to be a viable treatment strategy for certain cancers that over express es this receptor.
- E. V. Quadros, Y. Nakayama and J. M. Sequeira, “The Protein and the Gene Encoding the Receptor for the Cellular Uptake of Transcobalamin-Bound Cobalamin,” Blood, Vol. 113, No. 1, 2009, pp. 186-192. doi:10.1182/blood-2008-05-158949
- E. V. Quadros, S. P. Rothenberg and E. A. Jaffe, “Endothelial Cells from Human Umbilical Vein Secrete Functional Transcobalamin II,” American Journal of Physiology, Vol. 256, No. 2, 1989, pp. C296-303.
- E. V. Quadros, Y. Nakayama and J. M. Sequeira, “The Binding Properties of the Human Receptor for the Cellular Uptake of Vitamin B12,” Biochemical and Biophysical Research Communications, Vol. 327, No. 4, 2005, pp. 1006-1010. doi:10.1016/j.bbrc.2004.12.103
- K. Takahashi, M. Tavassoli and D. W. Jacobsen, “Receptor Binding and Internalization of Immobilized Transcobalamin II by Mouse Leukaemia Cells,” Nature, Vol. 288, No. 5792, 1980, pp. 713-715. doi:10.1038/288713a0
- T. Kishimoto, M. Tavassoli, R. Green and D. W. Jacobsen, “Receptors for Transferrin and Transcobalamin II Display Segregated Distribution on Microvilli of Leukemia L1210 Cells,” Biochemical and Biophysical Research Communications, Vol. 146, No. 3, 1987, pp. 1102-1108. doi:10.1016/0006-291X(87)90761-3
- E. V. Quadros, “Advances in the Understanding of Cobalamin Assimilation and Metabolism,” British Journal of Haematology, Vol. 148, No. 2, 2010, pp. 195-204. doi:10.1111/j.1365-2141.2009.07937.x
- J. Lindemans, A. C. Kroes, J. van Geel, J. van Kapel, M. Schoester, et al., “Uptake of Transcobalamin II-Bound Cobalamin by HL-60 Cells: Effects of Differentiation Induction,” Experimental Cell Research, Vol. 184, No. 2, 1989, pp. 449-460. doi:10.1016/0014-4827(89)90343-1
- T. Amagasaki, R. Green and D. W. Jacobsen, “Expression of Transcobalamin II Receptors by Human Leukemia K562 and HL-60 Cells,” Blood, Vol. 76, No. 7, 1990, pp. 1380-1386.
- C. A. Hall, P. D. Colligan and J. A. Begley, “Cyclic Activity of the Receptors of Cobalamin Bound to Transcobalamin II,” Journal of Cellular Physiology, Vol. 133, No. 1, 1987, pp. 187-191. doi:10.1002/jcp.1041330125
- W. Jiang, Y. Nakayama, J. M. Sequeira and E. V. Quadros, “Characterizing Monoclonal Antibodies to Antigenic Domains of TCblR/CD320, the Receptor for Cellular Uptake of Transcobalamin-Bound Cobalamin,” Drug Delivery, Vol. 18, No. 1, 2011, pp. 74-78. doi:10.3109/10717544.2010.509745
- E. V. Quadros, Y. Nakayama and J. M. Sequeira, “Targeted Delivery of Saporin Toxin by Monoclonal Antibody to the Transcobalamin Receptor, TCblR/CD320,” Molecular Cancer Therapeutics, Vol. 9, No. 11, 2010, pp. 3033-3040. doi:10.1158/1535-7163.MCT-10-0513